BioPharmX Demonstrates Topical Minocycline Gel May Exhibit Relevant Antimicrobial and Anti-inflammatory Properties for the Treatment of Acne at ASCB 2017
Cellular analysis suggests minocycline's antimicrobial properties and ability to modulate inflammatory cytokine secretion make it uniquely effective
Dec 4, 2017
MENLO PARK, Calif., Dec. 4, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share research suggesting that BPX-01, the company's topical gel formulation of minocycline, may exhibit relevant antimicrobial and anti-inflammatory properties for the treatment of acne. Data from cellular analysis shows minocycline's effectiveness may be due to its antimicrobial effect and its ability to modulate the effects of pro-inflammatory cytokines associated with acne pathology.
BioPharmX will share its findings in a poster entitled "BPX-01 Topical Minocycline Gel Reduces P. acnes-Induced Inflammatory Lesions in Mice" today at a conference hosted by the American Society for Cell Biology (ASBC) and European Molecular Biology Organization (EMBO) in Philadelphia, the company's first presentation of these data to the cellular biology community.
Study findings show that minocycline has anti-inflammatory activities in in vitro and animal models. Researchers identified two markers, cytokine IL-1 alpha and IL-6. P. acnes of inflammatory cytokine IL-1 alpha secretion in human keratinocytes. Researchers found that minocycline can decrease stimulated IL-1 alpha secretion and modulate the production of IL-6 in keratinocytes.
"Antibiotic resistance to topical clindamycin has become more prevalent in acne patients," said Kin F. Chan, executive vice president of research and technology at BioPharmX. "The development of a topical minocycline gel may provide an alternative with significant therapeutic benefits that are currently only available through the use of an oral formulation, which exposes patients to the risk of adverse side effects."
The 2017 ASCB/EMBO meeting is the largest gathering of cell scientists. The meeting is expected to attract 6,000 attendees from around the world.
BPX-011 is a hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that has been shown to penetrate the skin to deliver the antibiotic to its target. Following positive results from its previously announced phase 2b study of BPX-01 in acne, BioPharmX continues with phase 3 clinical study plans for BPX-01 for the treatment of acne.
About BioPharmX Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, the commencement and results of future trials of BPX-01 and the size of such trials, continued and consistent results in future tests of BPX-01 and absence of side effects of future use of BPX-01. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe" or similar expressions that are intended to identify such forward-looking statements.
These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017 and our quarterly report on Form 10-Q for the period ended July 31, 2017. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
1 Caution: BPX-01 is a new drug limited by U.S. law to investigational use.
SOURCE BioPharmX Corporation
For further information: Nina Brauer, email@example.com, (650) 889-5030, or Jim Martinez, firstname.lastname@example.org, (312) 543-9026